Investor Information Materials
 Tonix Pharmaceuticals
(Nasdaq: TNXP)
52-Week Range: $0.51-$2.46
Recent Price: $1.03
Approx. MktCap: $340 Million
Tonix expects to report the results of an interim analysis of its pivotal Phase 3 trial of TNX 102-SL in fibromyalgia in the coming quarter, with topline results due by year end. The trial’s enrollment goal is roughly 200 more participants than in the company’s first Phase 3, which significantly reduced fibromyalgia pain compared to placebo (p=0.01). Meantime, work is advancing on eleven other programs, including a predominantly T cell eliciting Covid-19 vaccine designed for ‘post pandemic’ immunity. It just completed a successful SARS CoV-2 challenge study in monkeys.

Webinar Video

After a brief update on Tonix's Phase 3 fibromyalgia program, CEO Seth Lederman, MD details the target profile for a 'post pandemic' Covid-19 vaccine with a historic nod to Dr. Edward Jenner, inventor of the original smallpox vaccine. (Approx. 22 minutes)

Q&A with Tonix CEO Seth Lederman, MD (Approx. 14 minutes)

Q&A Video 

TNXP At A Glance

Additional details on Tonix’s registration-directed clinical strategy in fibromyalgia, and why a live attenuated virus is Tonix’s technology of choice for a Covid-19 vaccine designed to confer long term immunity, and prevent forward expression, or contagion, a requirement to prevent the spread of any virus. Based on current data, antibody eliciting vaccines currently in use cannot make these claims.

Tonix Corporate Presentation

Slide Presentation

Visit Tonix's website

Important notice, please read: The information and statistical data contained herein may contain forward-looking statements that reflect the company’s intentions, expectations, assumptions, or beliefs concerning future events, including, but not limited to, expectations with respect to FDA and other regulatory bodies approval of new products, technology, and product development milestones, the ability of the company to leverage its product development and negotiate favorable collaborative agreements, the commencement of sales, the size of market opportunities with respect to the company’s product candidates and sufficiency of the company’s cash flow for future liquidity and capital resource needs and other risks identified in the Risk Factor Section of the company’s Annual Report on Form 10-K and any subsequent reports filed with the SEC. We do not undertake to advise you as to any change in this information. The forward-looking statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the company’s research and development programs. This is not a solicitation of any offer to buy or sell. Redington, Inc. is paid by subject company as an investor relations advisor, and its employees or members of their families may from time to time own an equity interest in companies mentioned herein.

Call 212 926-1733